Search
Now showing items 1-10 of 16
Syntheses of sulfanylphthalimide and xanthine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of adenosine receptors
(North-West University, 2013)
Currently L-DOPA is the drug most commonly used for the treatment of Parkinson’s disease (PD). However, the long-term use of L-DOPA is associated with the development of motor fluctuations and dyskinesias. Treatment mainly ...
Screening of virtual libraries for monoamine oxidase inhibitors
(2013)
The traditional view of drug design is that a single drug should interact with a single
molecular target. As science progressed, there was an understanding that most drugs
interact with more than one target and that ...
The antidepressant properties of selected methylene blue analogues
(2014)
The shortcomings of current antidepressant agents prompts the design of novel multimodal
antidepressants and the identification of new antidepressant targets, especially those
located at sub-cellular level. Such ...
Identification of monoamine oxidase inhibitors using a molecular modelling approach
(2014)
Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial membrane and is considered to be a target for the treatment of diseases such as Parkinson’s disease and depression. MAO may be classified into two ...
Monoamine oxidase inhibition by novel quinolinones
(2014)
Parkinson’s disease (PD) is an age-related neurodegenerative disorder. The degeneration of the neurons of the substantia nigra in the midbrain leads to the loss of dopamine from the striatum, which
is responsible for the ...
The monoamine oxidase inhibition properties of caffeine analogues containing saturated C–8 substituents
(North-West University, 2010)
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, characterized
pathologically by a marked loss of dopaminergic nigrostriatal neurons and clinically by disabling movement disorders. PD can be treated ...
Monoamine oxidase inhibition by indanone and benzoquinone analogues
(North-West University (South Africa) , Potchefstroom Campus, 2015)
Parkinson’s disease (PD) is a neurological disorder of which aging is the greatest risk factor. Over the next fifteen years, the number of persons affected by PD worldwide is expected to increase from 4.6 million to 9.3 ...
The design, synthesis and evaluation of aminocaffeine derivatives as inhibitors of monoamine oxidase B
(North-West University, 2011)
Monoamine oxidase (MAO) is responsible for dopamine catabolism in the brain and therefore is especially important in the treatment of Parkinson's disease (PD). MAO–B inhibition provides symptomatic relief by indirectly ...
Synthesis and biological evaluation of 6-substituted coumaranone derivatives and related compounds as monoamine oxidase inhibitors
(2014)
Parkinson’s disease (PD) is an age related neurodegenerative disorder that presents with both motor and non-motor symptoms. The most common pathological characteristic of PD is the loss of the pigmented dopaminergic neurons ...
The synthesis and evaluation of dual inhibitors of monoamine oxidase and catechol-O-methyltransferase
(North-West University (South Africa), Potchefstroom Campus, 2018)
Parkinson’s disease is the second most prevalent neurodegenerative disorder after Alzheimer’s disease. Parkinson’s disease is a debilitating, incurable, bradykinetic disorder which seriously inhibits a patient’s quality ...